Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Growing Prevalence Of Kidney Cancer Cases
3.2.2. Increasing Usages Of Minimally Invasive Processes
3.2.3. Surging Research And Development Expenditure
3.3. Key Restraints
3.3.1. High Costs Associated With The Treatment And Diagnosis Of Kidney Cancer
3.3.2. Low Rate Of Success In The Clinical Trials Of Kidney Cancer Drugs
3.3.3. Stringent Regulations

4. Key Analytics
4.1. Porter’S Five Force Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Impact Of Covid-19 On Kidney Cancer Therapeutics And Diagnostics
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Key Investment Insight

5. Market By Cancer Type
5.1. Clear Cell Rcc
5.2. Papillary Rcc
5.3. Chromophobe Rcc
5.4. Urothelial Carcinoma/Transitional Cell Carcinoma
5.5. Other Kidney Cancers

6. Market By Component
6.1. Drugs
6.1.1. Drugs By Therapeutic Class
6.1.1.1. Targeted Therapy
6.1.1.2. Immunotherapy
6.1.1.3. Other Therapeutic Class
6.1.2. Drugs By Pharmacologic Class
6.1.2.1. Angiogenesis Inhibitors
6.1.2.2. Mtor Inhibitors
6.1.2.3. Monoclonal Antibodies
6.1.2.4. Cytokine Immunotherapy (Il-2)
6.2. Diagnostics
6.2.1. Imaging Test
6.2.2. Biopsy
6.2.3. Blood Test
6.2.4. Other Diagnostics

7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
7.2. Europe
7.2.1. Germany
7.2.2. The United Kingdom
7.2.3. France
7.2.4. Italy
7.2.5. Russia
7.2.6. Belgium
7.2.7. Poland
7.2.8. Rest Of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. South Korea
7.3.5. Australia & New Zealand
7.3.6. Thailand
7.3.7. Indonesia
7.3.8. Vietnam
7.3.9. Rest Of Asia Pacific
7.4. Rest Of World
7.4.1. Latin America
7.4.2. Middle East & Africa

8. Company Profiles
8.1. Abbott Laboratories
8.2. Amgen Inc
8.3. Bayer Ag
8.4. Becton, Dickinson And Company (Bd)
8.5. Bristol-Myers Squibb Company
8.6. Exelixis
8.7. F. Hoffmann-La Roche
8.8. Merck & Co Inc
8.9. Merck Kgaa
8.10. Novartis International Ag
8.11. Nxstage Medical Inc
8.12. Pfizer Inc
8.13. Seattle Genetic



List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Global Kidney Cancer Therapeutics And Diagnostics Market, By Cancer Type, In 2019
Figure 5: Global Kidney Cancer Therapeutics And Diagnostics Market, By Clear Cell Rcc, 2019-2028 (In $ Million)
Figure 6: Global Kidney Cancer Therapeutics And Diagnostics Market, By Papillary Rcc, 2019-2028 (In $ Million)
Figure 7: Global Kidney Cancer Therapeutics And Diagnostics Market, By Chromophobe Rcc, 2019-2028 (In $ Million)
Figure 8: Global Kidney Cancer Therapeutics And Diagnostics Market, By Urothelial Carcinoma/Transitional Cell Carcinoma, 2019-2028 (In $ Million)
Figure 9: Global Kidney Cancer Therapeutics And Diagnostics Market, By Other Kidney Cancers, 2019-2028 (In $ Million)
Figure 10: Global Kidney Cancer Therapeutics And Diagnostics Market, By Component, In 2019
Figure 11: Global Kidney Cancer Therapeutics And Diagnostics Market, By Drugs, 2019-2028 (In $ Million)
Figure 12: Global Therapeutic Drug Class Market, By Targeted Therapy, 2019-2028 (In $ Million)
Figure 13: Global Therapeutic Drug Class Market, By Immunotherapy, 2019-2028 (In $ Million)
Figure 14: Global Therapeutic Drug Class Market, By Other Therapeutic Class, 2019-2028 (In $ Million)
Figure 15: Global Pharmacologic Class Market, By Angiogenesis Inhibitors, 2019-2028 (In $ Million)
Figure 16: Global Pharmacologic Class Market, By Mtor Inhibitors, 2019-2028 (In $ Million)
Figure 17: Global Pharmacologic Class Market, By Monoclonal Antibodies, 2019-2028 (In $ Million)
Figure 18: Global Pharmacologic Class Market, By Cytokine Immunotherapy (Il-2), 2019-2028 (In $ Million)
Figure 19: Global Kidney Cancer Therapeutics And Diagnostics Market, By Diagnostics, 2019-2028 (In $ Million)
Figure 20: Global Diagnostics Market, By Imaging Test, 2019-2028 (In $ Million)
Figure 21: Global Diagnostics Market, By Biopsy, 2019-2028 (In $ Million)
Figure 22: Global Diagnostics Market, By Blood Test, 2019-2028 (In $ Million)
Figure 23: Global Diagnostics Market, By Other Diagnostics, 2019-2028 (In $ Million)
Figure 24: North America Kidney Cancer Therapeutics And Diagnostics Market, Country Outlook, 2019 & 2028 (In %)
Figure 25: The United States Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 26: Canada Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 27: Europe Kidney Cancer Therapeutics And Diagnostics Market, Country Outlook, 2019 & 2028 (In %)
Figure 28: Germany Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 29: The United Kingdom Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 30: France Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 31: Italy Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 32: Russia Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 33: Belgium Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 34: Poland Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 35: Rest Of Europe Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 36: Asia Pacific Kidney Cancer Therapeutics And Diagnostics Market, Country Outlook, 2019 & 2028 (In %)
Figure 37: China Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 38: Japan Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 39: India Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 40: South Korea Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 41: Australia & New Zealand Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 42: Thailand Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 43: Indonesia Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 44: Vietnam Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 45: Rest Of Asia Pacific Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 46: Rest Of Kidney Cancer Therapeutics And Diagnostics Market, Regional Outlook, 2019 & 2028 (In %)
Figure 47: Latin America Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 48: Middle East & Africa Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
TABLE 2: RISK FACTORS DEVELOPING KIDNEY CANCER
TABLE 3: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 5: GLOBAL CLEAR CELL RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: GLOBAL CLEAR CELL RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 7: GLOBAL PAPILLARY RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 8: GLOBAL PAPILLARY RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 9: GLOBAL CHROMOPHOBE RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 10: GLOBAL CHROMOPHOBE RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 11: GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 12: GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 13: GLOBAL OTHER KIDNEY CANCERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 14: GLOBAL OTHER KIDNEY CANCERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 15: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 16: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 17: GLOBAL DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 18: GLOBAL DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 19: GLOBAL THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 20: GLOBAL THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 21: GLOBAL TARGETED THERAPY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 22: GLOBAL TARGETED THERAPY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 23: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 24: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 25: GLOBAL OTHER THERAPEUTIC CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 26: GLOBAL OTHER THERAPEUTIC CLASS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 27: GLOBAL PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 28: GLOBAL PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 29: GLOBAL ANGIOGENESIS INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 30: GLOBAL ANGIOGENESIS INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 31: GLOBAL MTOR INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 32: GLOBAL MTOR INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 33: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 34: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 35: GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2) MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 36: GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2) MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 37: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 38: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 39: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 40: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 41: GLOBAL IMAGING TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 42: GLOBAL IMAGING TEST MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 43: GLOBAL BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 44: GLOBAL BIOPSY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 45: GLOBAL BLOOD TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 46: GLOBAL BLOOD TEST MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 47: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 48: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 49: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 50: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 51: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 52: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 53: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 54: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 55: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 56: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 57: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 58: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)